Cancers can be treated in various ways depending on the type of cancer and how advanced the cancer is at diagnosis. Patients can be treated with a single treatment (monotherapy) or a combination of treatments. Common cancer treatments include surgery, chemotherapy, radiation, targeted therapy, hormonal therapy, and immunotherapy.
DATE: November 29, 2017TIME: 10:00 AM PSTThe three human RAS genes (HRAS, KRAS and NRAS) encode four highly related RAS small GTPases (HRAS, KRAS4A, KRAS4B and NRAS). RAS proteins funct...
DATE: November 16, 2017TIME: 9:00AM PT, 12:00PM ETThe wide use of 2D monolayer cultures for cancer drug discovery reflects the technical ease of implementation for drug screening, and t...
DATE: November 15, 2017TIME: 10:00AM PTInteractions between tumor and immune cells in the tumor microenvironment (TME) play a key role in tumor progression and treatment response, with...
Currently, prostate cancer is the second leading cause of death from cancer in North America, the most frequent malignancy in men from all ethnicities, surpassing lung cancer. Prostate tumors...
Despite the fact that screening for many cancers is associated with net harm, healthcare consumers continue to be screened. PSA is the most commonly performed laboratory screening test for ca...
DATE: October 19, 2017TIME: 7:00 AM PDT, 10:00 AM EDT, 4:00 PM CETThis is the second topic in the webinar series on ‘Sanger Sequencing & Fragment Analysis made easy’...
DATE: October 17, 2017TIME: 08:00am PDT, 11:00am EDTResearching and understanding the mechanisms of drug resistance are essential to determine therapies that are more effective on an in...
The promise of precision and personalized medicine is rooted in accurate, highly sensitive, and specific disease biomarkers. This is particularly true for cancer-a disease characterized by ma...
Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of only 9%. Acquired drug resistance is a major factor that limits the effectiveness of chemotherapy. Exosomes, secreted...
In order to expand the treatment options of cancers driven by oncogenic RAS, new cell surface targets need to be identified and characterized. Here, we describe mass spectrometry based phenot...
Pancreatic cancer is one of the “deadly” cancers, defined as those with a 5-year relative survival rate of less than 50%. Although ranking 12th in terms of incidence, it is...
Nanopore sequencing has enormous potential for application to cancer, but specifically offers advantages into two main arenas, epigenetics and structural variation. Methylation is well-known...
Immunotherapy: An unprecedented opportunity-Long-lasting/curative treatments-Lower side effects-Wide applicability-Natural mechanism of action-Locally produced T cell therapies&...
DATE: September 28, 2017TIME: 10:00am PDT, 1:00pm EDT The use of gene therapy is well studied due to its potential to treat cancer, the second leading cause of death worldwide....
Checkpoint blockade therapy for cancer has had tremendous impact on clinical outcomes, yet only a subset of patients respond. Recent studies show that response to checkpoint blockade does not...
Einstein researcher Robert Singer, Ph.D., discusses a breakthrough in microscopy that is allowing scientists to track messenger RNA in living cells in real time. The study, published in the S...
DATE: September 26, 2017TIME: 6:00AM PDTDespite a few decades of proteomics research and the apparent discovery of multiple protein biomarkers, the number of biomarkers that have been d...
DATE: September 21, 2017TIME: 8:00AM PSTBoard-certified hematologist-oncologist Ola Landgren, MD, PhD, will review how vague symptoms (fatigue, bone pain, back pain) are linked to...
DATE: September 13, 2017 TIME: 9:00AM SGT 12:00PM AEDTORDATE: September 12, 2017TIME: 6:00PM PDT To transform the promises of cell-based therapies int...
DATE: August 30, 2017TIME: 10:00am PT, 1:00pm ETRecent studies show that cancer cells can resist treatment by changing into a different cell type. Many treatments for specific cancers,...
The Instrumentation Group at the BC Cancer Agency’s Genome Sciences Centre (GSC) is unusual in having an engineering group and extensive prototyping facilities embedded in a biomedical...
The realization of the promise of personalized molecular medicine requires efficient development and implementation of novel targeted therapeutics linked to molecular markers able to identify...
DATE: May 9th, 2017TIME: 10:00AM PDT, 1:00PM ETMyeloproliferative neoplasms including myelofibrosis (MF) are characterized by anemia, splenomegaly, bone marrow fibrosis and inflammatory...
DATE: November 29, 2017TIME: 10:00 AM PSTThe three human RAS genes (HRAS, KRAS and NRAS) encode four highly related RAS small GTPases (HRAS, KRAS4A, KRAS4B and NRAS). RAS proteins funct...
DATE: November 16, 2017TIME: 9:00AM PT, 12:00PM ETThe wide use of 2D monolayer cultures for cancer drug discovery reflects the technical ease of implementation for drug screening, and t...
DATE: November 15, 2017TIME: 10:00AM PTInteractions between tumor and immune cells in the tumor microenvironment (TME) play a key role in tumor progression and treatment response, with...
Currently, prostate cancer is the second leading cause of death from cancer in North America, the most frequent malignancy in men from all ethnicities, surpassing lung cancer. Prostate tumors...
Despite the fact that screening for many cancers is associated with net harm, healthcare consumers continue to be screened. PSA is the most commonly performed laboratory screening test for ca...
DATE: October 19, 2017TIME: 7:00 AM PDT, 10:00 AM EDT, 4:00 PM CETThis is the second topic in the webinar series on ‘Sanger Sequencing & Fragment Analysis made easy’...
DATE: October 17, 2017TIME: 08:00am PDT, 11:00am EDTResearching and understanding the mechanisms of drug resistance are essential to determine therapies that are more effective on an in...
The promise of precision and personalized medicine is rooted in accurate, highly sensitive, and specific disease biomarkers. This is particularly true for cancer-a disease characterized by ma...
Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of only 9%. Acquired drug resistance is a major factor that limits the effectiveness of chemotherapy. Exosomes, secreted...
In order to expand the treatment options of cancers driven by oncogenic RAS, new cell surface targets need to be identified and characterized. Here, we describe mass spectrometry based phenot...
Pancreatic cancer is one of the “deadly” cancers, defined as those with a 5-year relative survival rate of less than 50%. Although ranking 12th in terms of incidence, it is...
Nanopore sequencing has enormous potential for application to cancer, but specifically offers advantages into two main arenas, epigenetics and structural variation. Methylation is well-known...
Immunotherapy: An unprecedented opportunity-Long-lasting/curative treatments-Lower side effects-Wide applicability-Natural mechanism of action-Locally produced T cell therapies&...
DATE: September 28, 2017TIME: 10:00am PDT, 1:00pm EDT The use of gene therapy is well studied due to its potential to treat cancer, the second leading cause of death worldwide....
Checkpoint blockade therapy for cancer has had tremendous impact on clinical outcomes, yet only a subset of patients respond. Recent studies show that response to checkpoint blockade does not...
Einstein researcher Robert Singer, Ph.D., discusses a breakthrough in microscopy that is allowing scientists to track messenger RNA in living cells in real time. The study, published in the S...
DATE: September 26, 2017TIME: 6:00AM PDTDespite a few decades of proteomics research and the apparent discovery of multiple protein biomarkers, the number of biomarkers that have been d...
DATE: September 21, 2017TIME: 8:00AM PSTBoard-certified hematologist-oncologist Ola Landgren, MD, PhD, will review how vague symptoms (fatigue, bone pain, back pain) are linked to...
DATE: September 13, 2017 TIME: 9:00AM SGT 12:00PM AEDTORDATE: September 12, 2017TIME: 6:00PM PDT To transform the promises of cell-based therapies int...
DATE: August 30, 2017TIME: 10:00am PT, 1:00pm ETRecent studies show that cancer cells can resist treatment by changing into a different cell type. Many treatments for specific cancers,...
The Instrumentation Group at the BC Cancer Agency’s Genome Sciences Centre (GSC) is unusual in having an engineering group and extensive prototyping facilities embedded in a biomedical...
The realization of the promise of personalized molecular medicine requires efficient development and implementation of novel targeted therapeutics linked to molecular markers able to identify...
DATE: May 9th, 2017TIME: 10:00AM PDT, 1:00PM ETMyeloproliferative neoplasms including myelofibrosis (MF) are characterized by anemia, splenomegaly, bone marrow fibrosis and inflammatory...
Follow
